PL3911751T3 - Indukowalne promotory specyficzne dla wątroby i sposoby ich stosowania - Google Patents

Indukowalne promotory specyficzne dla wątroby i sposoby ich stosowania

Info

Publication number
PL3911751T3
PL3911751T3 PL20701859.9T PL20701859T PL3911751T3 PL 3911751 T3 PL3911751 T3 PL 3911751T3 PL 20701859 T PL20701859 T PL 20701859T PL 3911751 T3 PL3911751 T3 PL 3911751T3
Authority
PL
Poland
Prior art keywords
liver
methods
inducible promoters
specific inducible
specific
Prior art date
Application number
PL20701859.9T
Other languages
English (en)
Inventor
Michael Roberts
Graham WHYTESIDE
Anne BRAAE
Original Assignee
AskBio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AskBio Inc. filed Critical AskBio Inc.
Publication of PL3911751T3 publication Critical patent/PL3911751T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20701859.9T 2019-01-18 2020-01-20 Indukowalne promotory specyficzne dla wątroby i sposoby ich stosowania PL3911751T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1900741.8A GB201900741D0 (en) 2019-01-18 2019-01-18 Liver-specifc inducible prometers and methods of use thereof
PCT/GB2020/050107 WO2020148555A1 (en) 2019-01-18 2020-01-20 Liver-specific inducible promoters and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3911751T3 true PL3911751T3 (pl) 2025-08-11

Family

ID=65528320

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20701859.9T PL3911751T3 (pl) 2019-01-18 2020-01-20 Indukowalne promotory specyficzne dla wątroby i sposoby ich stosowania

Country Status (16)

Country Link
US (1) US12472269B2 (pl)
EP (2) EP3911751B1 (pl)
JP (2) JP7525768B2 (pl)
KR (1) KR20210122801A (pl)
CN (1) CN113614234A (pl)
AU (1) AU2020209490A1 (pl)
BR (1) BR112021014033A2 (pl)
CA (1) CA3126886A1 (pl)
ES (1) ES3021683T3 (pl)
GB (1) GB201900741D0 (pl)
IL (2) IL284880B1 (pl)
MX (1) MX2021008653A (pl)
PH (1) PH12021551701A1 (pl)
PL (1) PL3911751T3 (pl)
SG (1) SG11202107689RA (pl)
WO (1) WO2020148555A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900741D0 (en) * 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof
KR20260013512A (ko) * 2023-04-17 2026-01-28 아스크바이오 인크. 영장류에서의 트랜스진의 조절가능한 제어된 발현
IT202300013152A1 (it) 2023-06-26 2024-12-26 Univ Degli Studi Cagliari Tiazolidinoni come agenti antivirali
CN117925624B (zh) * 2024-03-22 2024-05-31 上海凌医生物科技有限公司 一种金属响应调控元件

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IT1258959B (it) 1992-06-09 1996-03-11 Impianto a moduli mobili per lo sviluppo e la produzione di prodotti biotecnologici su scala pilota
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
US20040006775A1 (en) * 2001-09-21 2004-01-08 Moore David D. Screening systems and methods for identifying modulators of xenobiotic matabolism
US7186879B2 (en) * 2000-09-21 2007-03-06 Baylor College Of Medicine Screening systems and methods for identifying modulators of xenobiotic metabolism
EP1719025B1 (en) 2004-02-03 2019-10-23 GE Healthcare Bio-Sciences Corp. System and method for manufacturing
CN101001945B (zh) 2004-06-04 2012-02-08 艾克塞勒雷克斯公司 一次性生物反应器系统及方法
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法
US20090305626A1 (en) 2005-12-05 2009-12-10 Hope Ernest G Prevalidated, modular good manufacturing practice-compliant facility
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
EP3586868B1 (en) 2008-04-22 2023-11-08 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
WO2011119773A1 (en) * 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
US8771635B2 (en) 2010-04-26 2014-07-08 Toyota Motor Engineering & Manufacturing North America, Inc. Hydrogen release from complex metal hydrides by solvation in ionic liquids
US10371394B2 (en) 2010-09-20 2019-08-06 Biologics Modular Llc Mobile, modular cleanroom facility
EP2479278A1 (en) 2011-01-25 2012-07-25 Synpromics Ltd. Method for the construction of specific promoters
US9388373B2 (en) 2011-03-08 2016-07-12 University Of Maryland Baltimore County Microscale bioprocessing system and method for protein manufacturing
CN102321732A (zh) 2011-06-20 2012-01-18 东北农业大学 一种猪car激动剂的高通量筛选方法
JP6836990B2 (ja) * 2014-11-26 2021-03-03 アクセラレイテッド・バイオサイエンシズ・コーポレーション 誘導肝細胞およびそれらの使用
KR102766526B1 (ko) 2015-10-28 2025-02-13 상가모 테라퓨틱스, 인코포레이티드 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
GB201900741D0 (en) * 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof

Also Published As

Publication number Publication date
US20220111078A1 (en) 2022-04-14
GB201900741D0 (en) 2019-03-06
JP7525768B2 (ja) 2024-07-31
SG11202107689RA (en) 2021-08-30
CA3126886A1 (en) 2020-07-23
PH12021551701A1 (en) 2022-03-21
EP4541898A3 (en) 2025-06-25
IL284880B1 (en) 2025-11-01
AU2020209490A1 (en) 2021-08-12
JP2024133073A (ja) 2024-10-01
IL284880A (en) 2021-08-31
BR112021014033A2 (pt) 2021-09-21
JP2022523639A (ja) 2022-04-26
KR20210122801A (ko) 2021-10-12
US12472269B2 (en) 2025-11-18
ES3021683T3 (en) 2025-05-27
WO2020148555A1 (en) 2020-07-23
EP3911751A1 (en) 2021-11-24
IL323952A (en) 2025-12-01
EP3911751C0 (en) 2025-02-26
MX2021008653A (es) 2021-11-03
CN113614234A (zh) 2021-11-05
EP3911751B1 (en) 2025-02-26
EP4541898A2 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
IL287407A (en) Chimeric receptors and methods of using them
IL276731A (en) Antibodies against CD73 and methods of using them
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
SG11202103151RA (en) Frataxin expression constructs having engineered promoters and methods of use thereof
IL283278B1 (en) Liver-unique promoters and their uses
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
SG11202107689RA (en) Liver-specific inducible promoters and methods of use thereof
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL285730A (en) Compounds with proptosis-inducing activity and methods of using them
SG11202112978WA (en) Auto-injector and related methods of use
SG11202109568TA (en) Pyridazinones and methods of use thereof
IL287282A (en) Anti-mertk antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL288886A (en) Antibodies and methods of use
IL276053A (en) Therapeutic Gard and methods of its use
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
GB2589398B (en) Compounds and methods of use